Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Cormedix, Lowers Price Target to $12

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $20 to $12.
byBenzinga Newsdesk
August 9, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $20 to $12.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

FDA Denies Marketing of Six Flavored Vuse Alto E-Cigarette Products Following Determination They Do Not Meet Public Health Standard

By Benzinga Newsdesk
October 12, 11:41 AM
Today, the U.S. Food and Drug Administration issued marketing denial orders (MDOs) to R.J. Reynolds Vapor Company for six flavored e-cigarette products under its Vuse Alto brand. This includes three menthol-flavored and three mixed berry-flavored products, with each flavor being offered in three nicotine strengths.

MO